ADC Therapeutics SA (ADCT)
NYSE: ADCT · IEX Real-Time Price · USD
4.340
-0.100 (-2.25%)
At close: Apr 26, 2024, 4:00 PM
4.460
+0.120 (2.76%)
After-hours: Apr 26, 2024, 7:51 PM EDT
ADC Therapeutics Revenue
In the year 2023, ADC Therapeutics had annual revenue of $69.56M, a decrease of -66.86%. Revenue in the quarter ending December 31, 2023 was $16.79M, a -75.94% decrease year-over-year.
Revenue (ttm)
$69.56M
Revenue Growth
-66.86%
P/S Ratio
5.17
Revenue / Employee
$254,791
Employees
273
Market Cap
359.41M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 69.56M | -140.35M | -66.86% |
Dec 31, 2022 | 209.91M | 175.99M | 518.89% |
Dec 31, 2021 | 33.92M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 2.34M | 1.20M | 105.26% |
Dec 31, 2018 | 1.14M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Amarin Corporation | 306.91M |
Zynex | 184.32M |
Harrow Health | 130.19M |
Heron Therapeutics | 127.04M |
Aquestive Therapeutics | 50.58M |
Mersana Therapeutics | 36.86M |
Cartesian Therapeutics | 26.00M |
Immutep | 4.58M |
ADCT News
- 22 days ago - ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma - GlobeNewsWire
- 23 days ago - ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024 - GlobeNewsWire
- 6 weeks ago - ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 weeks ago - ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit - GlobeNewsWire
- 7 weeks ago - ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024 - GlobeNewsWire
- 7 weeks ago - ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 2 months ago - ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference - GlobeNewsWire
- 3 months ago - Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth - CNBC